Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Shanghai Pharmaceuticals Holding Co Ltd
Accounts Payable
Shanghai Pharmaceuticals Holding Co Ltd
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
Accounts Payable
¥64.5B
|
CAGR 3-Years
13%
|
CAGR 5-Years
12%
|
CAGR 10-Years
12%
|
|
|
Sinopharm Group Co Ltd
HKEX:1099
|
Accounts Payable
¥152.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
|
Jointown Pharmaceutical Group Co Ltd
SSE:600998
|
Accounts Payable
¥52.9B
|
CAGR 3-Years
47%
|
CAGR 5-Years
28%
|
CAGR 10-Years
23%
|
|
|
C
|
China National Medicines Corp Ltd
SSE:600511
|
Accounts Payable
¥12B
|
CAGR 3-Years
9%
|
CAGR 5-Years
8%
|
CAGR 10-Years
20%
|
|
|
Huadong Medicine Co Ltd
SZSE:000963
|
Accounts Payable
¥8.8B
|
CAGR 3-Years
23%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
|
C
|
China National Accord Medicines Corp Ltd
SZSE:000028
|
Accounts Payable
¥21.4B
|
CAGR 3-Years
20%
|
CAGR 5-Years
16%
|
CAGR 10-Years
16%
|
|
Shanghai Pharmaceuticals Holding Co Ltd
Glance View
Shanghai Pharmaceuticals Holding Co Ltd, a giant in China's pharmaceutical industry, operates with a dual-engine strategy that seamlessly combines manufacturing and distribution. Established in the bustling metropolis of Shanghai, the company has swiftly become a cornerstone of China's healthcare landscape. Its manufacturing arm is a powerhouse of innovation and production, turning out a vast array of pharmaceutical products that encompass both traditional Chinese medicine and modern pharmaceuticals. These products range from patented medicines to essential generics, entering hospitals, clinics, and retail pharmacies nationwide, all the while feeding a robust supply chain that caters to the country's vast and diverse market needs. On the flip side, Shanghai Pharmaceuticals' extensive distribution network is the lifeline that ensures these vital medicines reach their destinations safely and efficiently. In an era where logistics and supply chain management are pivotal, the company excels through an advanced distribution system that connects manufacturers with end-users across China. This network is bolstered by strategic partnerships and a commitment to technological advancement, allowing the company to maintain agility and reliability in an ever-evolving market. Revenue streams flow not just from product sales but are heavily supplemented through strategic partnerships and services that enhance accessibility and affordability for healthcare providers and patients alike. As one of the top pharmaceutical firms in China, Shanghai Pharmaceuticals is adept at maneuvering the intricacies of healthcare demands, regulatory landscapes, and competitive dynamics, carving its niche as a leader in both innovation and distribution efficiency.
See Also
What is Shanghai Pharmaceuticals Holding Co Ltd's Accounts Payable?
Accounts Payable
64.5B
CNY
Based on the financial report for Sep 30, 2025, Shanghai Pharmaceuticals Holding Co Ltd's Accounts Payable amounts to 64.5B CNY.
What is Shanghai Pharmaceuticals Holding Co Ltd's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
12%
Over the last year, the Accounts Payable growth was 5%. The average annual Accounts Payable growth rates for Shanghai Pharmaceuticals Holding Co Ltd have been 13% over the past three years , 12% over the past five years , and 12% over the past ten years .